A potential rise of breast cancer risk in the UAE post-COVID-19 lockdown: A call for action

Ennab, Farah; Tsagkaris, Christos; Babar, Maryam Salma; Tazyeen, Saema; Kokash, Diana Mutasem; Mago, Arpit; Nawaz, Faisal A.; Al-Shamsi, Humaid O.

doi:10.1016/j.amsu.2022.103976

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other notable publications include the first pre-chemotherapy COVID-19 screening study, which was published in JAMA Oncology and was one of the trending articles at the time of its publication [ 84 , 85 ]. Other publications from the UAE have also been published in regional and international journals [ 86 , 87 , 88 , 89 , 90 , 91 ].…”

Section: Covid-19 and Cancer Care In Uaementioning

confidence: 99%

“…The UAE is a desirable destination for healthcare, especially for African and Iraqi patients. The UAE’s health system is ranked 27th in the world by the WHO [ 86 ]. The UAE government has launched medical tourism portals that allow international patients to book procedures and access a wide range of tourism services, such as direct contact with healthcare providers, visa issuance, booking appointments, hotels, transportation, and other recreational activities [ 87 ].…”

Section: Medical Tourism For Cancer Care In the Uaementioning

confidence: 99%

See 1 more Smart Citation

The State of Cancer Care in the United Arab Emirates in 2022

Al-Shamsi

2022

Clinics and Practice

Self Cite

View full text Add to dashboard Cite

Cancer is the third-leading cause of death in the United Arab Emirates (UAE); cancer care in the UAE has evolved dramatically over the last 40 years, from a single center in Al Ain in 1981 to more than 30 cancer centers and clinics across the UAE, with at least four comprehensive cancer centers in the UAE nowadays. Despite the significant progress in medical care, cancer quality control across the UAE is still lacking, with significant variations in cancer care across the cancer centers. Access to clinical trials is still hampered by a lack of expertise and research infrastructure and a small population, which renders patient accrual for trials a major challenge. Education and training are other areas for improvement that require immediate attention, and, in this review, we try to address these critical aspects for stakeholders to consider better cancer care in the UAE. Early cancer detection and screening are still evolving in the UAE, and a national screening program is lacking. There is also a need to address barriers to screening and to consider less invasive screening methods such as approved blood-based screening, which is likely to be more acceptable to the UAE population. In this review, we also address new topics that have not been addressed previously, including oncology medical tourism, psycho-oncology, onco-fertility, precision oncology, survivorship, oncology nursing, cancer support programs, and the oncology sector’s response to the COVID-19 pandemic, all in the context of the UAE cancer landscape. Finally, we provide recommendations for policymakers, regulators, payers, patient advocacy groups, and the UAE oncology community regarding the delivery and future planning of high-quality cancer care. These recommendations are aligned with the UAE government’s vision to reduce cancer mortality and provide high-quality healthcare for its citizens and residents.

show abstract

Section: Covid-19 and Cancer Care In Uaementioning

confidence: 99%

Section: Medical Tourism For Cancer Care In the Uaementioning

confidence: 99%

The State of Cancer Care in the United Arab Emirates in 2022

Al-Shamsi

2022

Clinics and Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…This makes breast cancer the first or second leading cause of female cancer deaths in 95% of countries and the fifth most common cause of cancer death overall globally [ 9 , 10 ]. In the United Arab Emirates (UAE), breast cancer accounts for the most diagnosed cancer in both sexes with 21.4% and 38.8% in females of all ages according to the WHO in 2020 [ 11 , 12 ]. It was the leading cause of cancer death in 2019, with an estimated average of 11.6% of cancer deaths yearly [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Histopathological Profile of Different Breast Lesions: A Single-Center Observational Study

Ibrahim,

Ali,

Sharbatti

et al. 2024

Cureus

View full text Add to dashboard Cite

Objective: To describe the histopathological pattern of different breast lesions among tissue specimens sent to our laboratory. Method: A record-based study using a retrospective review of 255 histologically diagnosed breast biopsy reports in the histopathology department of authors from December 2016 to November 2021 was conducted. The specimens were collected from core biopsy, lumpectomy, and mastectomy. All data obtained were analyzed using the Statistical Package for the Social Sciences (SPSS) version 28 (IBM SPSS Statistics, Armonk, NY). Then, the findings were presented using text, tables, and charts. Result: A total of 255 breast lesions were analyzed in this study. Most of the cases were benign (58.8%), followed by inflammatory lesions (21.6%), and malignant (19.6%). Fibroadenoma was the most prevalent benign lesion (36.7%), and most of the patients (70.9%) were in the age group of 20-39 years old. The most common inflammatory lesion was granulomatous mastitis (56.4%), and most of the cases were diagnosed in the age group of 30-39 years old. Invasive ductal carcinoma (IDC) was the most encountered histological type of carcinoma (62%). Of the malignant cases, 52% were diagnosed before the age of 50 years. Among these 50 cases, grade 2 was the most prevalent one (46%). Conclusion: Benign breast lesions are more common than malignant breast lesions, and fibroadenoma is the most common benign subtype. Granulomatous mastitis is the most prevalent inflammatory breast lesion. About two-thirds of malignant cases are non-Arab. Invasive ductal carcinoma with no special type (NST) is the most common malignant subtype.

show abstract

“…In United Arab Emirates (UAE), BC cases were at 21.4% incidence in 2020 [ 2 ]. A recent study indicated an increase in BC risk among Emirati woman post-coronavirus disease 2019 (COVID-19) [ 3 ]. Other studies from the hospitals in the region informed in the increase in delay in the presentation of BC and the number of late-stage BC among young women [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Association Between Expression of Vitamin D Receptor and Insulin-Like Growth Factor 1 Receptor Among Breast Cancer Patients

et al. 2023

View full text Add to dashboard Cite

Background: Vitamin D receptor (VDR) and insulin-like growth factor 1 receptor (IGF1R) are known to be involved in breast cancer (BC) progression. Our previous work reported a correlation of differential localization of IGF1R with hormone receptor status in BC. A recent report described VDR and IGF1R as potential indicators of BC prognosis, but their interplay was not discussed. The present study focused on understanding the association of VDR expression with IGF1R activation, different molecular markers, and subtypes of BC.Methods: A retrospective study was designed to evaluate the VDR expression among 48 BC patients pathologically diagnosed as invasive BC and were surgically treated at Sharjah Breast Care Center, University Hospital Sharjah (UHS), United Arab Emirates (UAE). Formalinfixed paraffin-embedded (FFPE) tumor blocks with appropriate clinicopathological data were subjected to immunohistochemistry (IHC), and VDR protein expression was interpreted based on the staining intensity (SI) and the percentage of the positively stained cells (PP).Results: Nearly 44% of cases in the study were vitamin D deficient. A positive VDR expression with strong intensity (score > 4) was seen in 27 cases (56.3%). The expression pattern for VDR was equally distributed in cytoplasm and nucleus. For the IGF1R intensity, 24 cases (50%) of total cohort showed strong expression. A significant association was detected between IGF1R and VDR expression (P = 0.031). Conclusions:The present study identified positive association between IGF1R and VDR expression where most of the cases with strong VDR expression displayed strong IGF1R expression. These findings may contribute to current understanding on the role of VDR in BC and its interaction with IGF1R.

show abstract

A potential rise of breast cancer risk in the UAE post-COVID-19 lockdown: A call for action

Cited by 4 publications

References 19 publications

The State of Cancer Care in the United Arab Emirates in 2022

The State of Cancer Care in the United Arab Emirates in 2022

Histopathological Profile of Different Breast Lesions: A Single-Center Observational Study

Association Between Expression of Vitamin D Receptor and Insulin-Like Growth Factor 1 Receptor Among Breast Cancer Patients

Contact Info

Product

Resources

About